The tumor and plasma cytokine profiles of renal cell carcinoma patients.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 08 2022
04 08 2022
Historique:
received:
10
03
2022
accepted:
27
07
2022
entrez:
4
8
2022
pubmed:
5
8
2022
medline:
9
8
2022
Statut:
epublish
Résumé
Renal cell carcinoma (RCC) accounts for 90% of all renal cancers and is considered highly immunogenic. Although many studies have reported the circulating peripheral cytokine profiles, the signatures between the tumor tissue and matching healthy adjacent renal tissue counterparts have not been explored. We aimed to comprehensively investigate the cytokine landscape of RCC tumors and its correlation between the amount and phenotype of the tumor infiltrating lymphocytes (TILs). We analyzed the secretion of 42 cytokines from the tumor (n = 46), adjacent healthy kidney tissues (n = 23) and matching plasma samples (n = 33) with a Luminex-based assay. We further explored the differences between the tissue types, as well as correlated the findings with clinical data and detailed immunophenotyping of the TILs. Using an unsupervised clustering approach, we observed distinct differences in the cytokine profiles between the tumor and adjacent renal tissue samples. The tumor samples clustered into three distinct profiles based on the cytokine expressions: high (52.2% of the tumors), intermediate (26.1%), and low (21.7%). Most of the tumor cytokines positively correlated with each other, except for IL-8 that showed no correlation with any of the measured cytokine expressions. Furthermore, the quantity of lymphocytes in the tumor samples analyzed with flow cytometry positively correlated with the chemokine-family of cytokines, CXCL10 (IP-10) and CXCL9 (MIG). No significant correlations were found between the tumor and matching plasma cytokines, suggesting that circulating cytokines poorly mirror the tumor cytokine environment. Our study highlights distinct cytokine profiles in the RCC tumor microenvironment and provides insights to potential biomarkers for the treatment of RCC.
Identifiants
pubmed: 35927313
doi: 10.1038/s41598-022-17592-3
pii: 10.1038/s41598-022-17592-3
pmc: PMC9352752
doi:
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13416Informations de copyright
© 2022. The Author(s).
Références
Vaccines (Basel). 2016 Jun 24;4(3):
pubmed: 27348007
Nat Rev Clin Oncol. 2018 May;15(5):310-324
pubmed: 29434333
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33688021
Cancer Gene Ther. 2007 Aug;14(8):696-705
pubmed: 17514193
Front Immunol. 2019 Jun 18;10:1338
pubmed: 31275311
Nat Med. 2019 Dec;25(12):1822-1832
pubmed: 31806905
Eur J Surg Oncol. 2016 May;42(5):744-50
pubmed: 26899942
J Clin Oncol. 2004 Aug 15;22(16):3316-22
pubmed: 15310775
Eur Urol. 2012 Aug;62(2):303-14
pubmed: 22575911
Oncoimmunology. 2018 Nov 5;8(2):e1537691
pubmed: 30713794
Nat Med. 2020 May;26(5):688-692
pubmed: 32405062
Oncoimmunology. 2022 Jan 4;11(1):1993042
pubmed: 35003893
J Urol. 2002 Dec;168(6):2395-400
pubmed: 12441925
Cancer Res. 2019 Sep 15;79(18):4557-4566
pubmed: 31350295
Sci Rep. 2015 Mar 17;5:9188
pubmed: 25776849
Oncoimmunology. 2015 Nov 24;5(3):e1115177
pubmed: 27141367
J Transl Med. 2007 Oct 22;5:51
pubmed: 17953739
Nat Med. 2020 May;26(5):693-698
pubmed: 32405063
J Clin Pathol. 2004 May;57(5):504-12
pubmed: 15113858
Nat Med. 2020 May;26(5):650-651
pubmed: 32405061
Cancer Treat Rev. 2018 Feb;63:40-47
pubmed: 29207310
Lab Invest. 2006 Dec;86(12):1221-32
pubmed: 17075581
Nat Rev Cancer. 2004 Jan;4(1):11-22
pubmed: 14708024